- Home
- CPRI vs TMDX Comparison
CPRI vs TMDX Comparison
Compare CPRI & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRI
- TMDX
- Stock Information
- Founded
- CPRI 1981
- TMDX 1998
- Country
- CPRI United Kingdom
- TMDX United States
- Employees
- CPRI N/A
- TMDX N/A
- Industry
- CPRI Apparel
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CPRI Consumer Discretionary
- TMDX Health Care
- Exchange
- CPRI Nasdaq
- TMDX Nasdaq
- Market Cap
- CPRI 2.6B
- TMDX 2.7B
- IPO Year
- CPRI 2011
- TMDX 2019
- Fundamental
- Price
- CPRI $21.77
- TMDX $62.71
- Analyst Decision
- CPRI Hold
- TMDX Buy
- Analyst Count
- CPRI 10
- TMDX 11
- Target Price
- CPRI $27.90
- TMDX $116.10
- AVG Volume (30 Days)
- CPRI 3.8M
- TMDX 1.9M
- Earning Date
- CPRI 02-06-2025
- TMDX 10-28-2024
- Dividend Yield
- CPRI N/A
- TMDX N/A
- EPS Growth
- CPRI N/A
- TMDX N/A
- EPS
- CPRI N/A
- TMDX 0.94
- Revenue
- CPRI $4,796,000,000.00
- TMDX $401,090,000.00
- Revenue This Year
- CPRI N/A
- TMDX $82.52
- Revenue Next Year
- CPRI $1.02
- TMDX $25.91
- P/E Ratio
- CPRI N/A
- TMDX $70.11
- Revenue Growth
- CPRI N/A
- TMDX 109.09
- 52 Week Low
- CPRI $18.70
- TMDX $60.80
- 52 Week High
- CPRI $51.23
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- CPRI 42.11
- TMDX 31.44
- Support Level
- CPRI $20.98
- TMDX $60.80
- Resistance Level
- CPRI $23.12
- TMDX $66.44
- Average True Range (ATR)
- CPRI 0.80
- TMDX 4.10
- MACD
- CPRI 0.33
- TMDX 0.50
- Stochastic Oscillator
- CPRI 31.65
- TMDX 13.30
About CPRI Capri Holdings Limited
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.